Form 4: Kevin Gorman Exercises and Sells NBIX Shares

Director Kevin Gorman exercised options for 205,088 shares and sold a total of 245,088 shares of Neurocrine Biosciences.

Summary

• Director Kevin Gorman exercised stock options for 205,088 shares of Neurocrine Biosciences (NBIX) at a price of $43.24 per share.
• Following the exercise, the director sold 245,088 shares at a weighted average price of $154.3318 per share.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2026.
• Post-transaction, the director maintains beneficial ownership of 511,293 shares held via the Gorman and Blais Family Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine insider transaction executed under a pre-established plan, which carries no significant signal regarding company performance.

Positives

• The director maintains a significant remaining stake of 511,293 shares in the company.
• The transaction was conducted through a pre-arranged Rule 10b5-1 plan, indicating a systematic approach to liquidity rather than reactive selling.

Negatives

• The transaction represents a net reduction in the director's direct equity holdings.

Risks

• The expiration of stock options in February 2027 necessitates periodic exercise to capture value, which may lead to continued selling pressure.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for executives to manage personal liquidity and diversify portfolios, and is generally viewed as neutral by the market when pre-planned.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to avoid allegations of trading on material non-public information.
• The scale of the sale is consistent with typical executive compensation and equity management cycles for mid-to-large cap biotechnology firms.

Stakeholder Impact

• Shareholders should note the reduction in insider holdings, though the remaining stake remains substantial.

Next Steps

• No further actions required by the reporting person regarding this specific transaction.

Key Dates

Keywords

NBIX, Neurocrine Biosciences, Insider Trading, Form 4, Stock Options, Rule 10b5-1